Filing Analysis
GT Biopharma, Inc. amended its bylaws on June 8, 2026, to significantly lower the quorum requirement for stockholder meetings from a majority of outstanding shares to one-third (1/3). The company states this change is necessary due to difficulties in obtaining a quorum caused by brokerage firms' voting behaviors.
🚩 Red Flags
- Significant reduction in quorum requirements can be a red flag for micro-cap companies, as it makes it easier for a small minority of shareholders or insiders to pass resolutions without broad shareholder consent
- The company operates as a 'fully remote company' without a principal executive office, which can be an operational risk for a biotech firm
📋 Key Facts
- Amendment effective date: June 8, 2026
- Quorum requirement reduced from >50% to >=33.3% (one-third) of outstanding shares
- The company is now fully remote as of July 1, 2024, with no physical principal executive office
- The filing was signed by CFO Alan Urban on June 12, 2026
GT Biopharma, Inc. (GTBP) received a second Nasdaq deficiency notice on May 20, 2026, granting an additional 180-day compliance period (until November 16, 2026) to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This follows an initial 180-day compliance period that began November 20, 2025 and expired May 19, 2026, during which the company failed to regain compliance. The company is now in its final extension period, after which delisting proceedings could commence if compliance is not achieved.
🚩 Red Flags
- This is the SECOND consecutive 180-day compliance period, indicating persistent failure to maintain minimum bid price — a strong indicator of potential delisting
- Stock has been below $1.00 per share for over 6 months (since at least mid-October 2025), suggesting deeply distressed share price
- Company explicitly disclaims any assurance of regaining compliance or maintaining compliance with other Nasdaq rules
- No concrete remediation plan disclosed — company only states it will 'monitor' the stock price and 'assess available options'
- Reverse stock split is the most common remediation tool at this stage, which would be dilutive/unfavorable for existing shareholders
- Company has no physical principal executive office (fully remote since July 1, 2024), which may reflect resource constraints
- Filing covers multiple 8-K items (3.01 and 9.01), consistent with a formal regulatory action
📋 Key Facts
- On May 20, 2026, GTBP received a second Nasdaq deficiency letter granting an additional 180-day compliance period
- New compliance deadline is November 16, 2026 under Nasdaq Listing Rule 5550(a)(2)
- Compliance requires the closing bid price to reach at least $1.00 per share for a minimum of 10 consecutive business days
- Initial 180-day compliance period was granted November 20, 2025 and expired May 19, 2026 without compliance being achieved
- Stock has been trading below $1.00 per share for at least 30 consecutive business days as of the original notice date
- Nasdaq confirmed the company meets all other continued listing requirements, including market value of publicly held shares
- Company states 'there can be no assurance' it will regain compliance or remain compliant with other Nasdaq listing rules
- Company became fully remote effective July 1, 2024 and has no principal executive office
- Filing signed by Alan Urban, Chief Financial Officer, on May 22, 2026
- Company is incorporated in Delaware and listed on Nasdaq Capital Market (Commission File No. 1-40023)
GT Biopharma entered into a $3.8 million Investigator Initiated Clinical Trial Agreement with the University of Minnesota to conduct a Phase 1a/1b clinical trial for its GTB-5550 drug candidate. The University will sponsor the IND application and lead the research program targeting advanced solid tumors over a three-year period.
🚩 Red Flags
- The Company transitioned to a fully remote model as of July 1, 2024, and does not maintain a principal executive office.
- The University has the right to terminate the agreement immediately for health, welfare, and safety reasons.
📋 Key Facts
- Agreement signed on April 3, 2026, with the Regents of the University of Minnesota.
- The study focuses on GTB-5550, a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE®).
- The Company is committed to a budget of approximately $3.8 million over three years.
- The University will sponsor the Investigational New Drug (IND) application (IND 169118).
- The trial is a Phase 1a/1b study for advanced solid tumors that have failed prior therapy.
GT Biopharma is restating its financial statements for the second and third quarters of 2025 due to the misclassification of stock purchase rights ('Greenshoe Rights') as equity instead of liabilities. The correction results in a massive non-cash increase in net loss for the first half of 2025, though it does not impact the company's cash position.
🚩 Red Flags
- Material restatement of previously issued financial statements (Item 4.02).
- Significant accounting error involving complex financial instruments (ASC 480 compliance).
- Massive adjustment to net loss ($28.7M) relative to total assets ($7.1M).
- Accumulated deficit reached $718.1 million as of September 30, 2025.
📋 Key Facts
- The restatement affects Quarterly Reports on Form 10-Q for the periods ended June 30, 2025, and September 30, 2025.
- The error relates to Series L 10% Convertible Preferred Stock purchase rights issued in May 2025 which required liability classification under ASC 480.
- For the three months ended June 30, 2025, net loss was adjusted from $1.4 million to $30.2 million, a $28.7 million increase.
- Net loss per share for the six months ended June 30, 2025, was restated from $0.90 to $12.12.
- The company became fully remote as of July 1, 2024, and no longer maintains a principal executive office.
- The Greenshoe Rights liability was extinguished and reclassified to equity in September 2025 after a redemption rights waiver.